Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients

Authors: Hiramatsu, S.¹; Tajiri, Y.²; Karashima, T.¹

Source: Diabetes, Obesity and Metabolism, Volume 6, Number 3, May 2004 , pp. 231-233(3)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Aim:

To investigate clinical efficacy of pioglitazone in association with plasma adiponectin concentration in type 2 diabetic patients. Methods:

Ten diabetic patients were treated with 15 or 30 mg of pioglitazone for 8 weeks, and association between plasma adiponectin concentration before treatment and decrease in glycated albumin levels was examined. Results:

Treatment with pioglitazone for 8 weeks lowered glycated albumin level (27.1 ± 1.2 to 23.8 ± 1.4%, p < 0.05), and inverse relationship between changes in glycated albumin and plasma adiponectin concentration before treatment was revealed (r = −0.66, p < 0.05). Plasma adiponectin concentrations of patients whose glycated albumin level reduced by more than 10% of the levels before treatment were significantly lower than those of patients whose glycaemic control was affected less (5.2 ± 0.6 vs. 8.0 ± 1.0 µg/ml, p < 0.05). Conclusion:

Lower plasma adiponectin concentration predicts the clinical efficacy of pioglitazone.

Keywords: adiponectin; diabetes mellitus; diabetes treatment; insulin resistance

Document Type: Short communication

DOI: http://dx.doi.org/10.1111/j.1462-8902.2004.00333.x

Affiliations: 1: Department of Metabolism and Endocrinology, Department of Clinical Research, National Kyushu Medical Centre, Fukuoka, Japan 2: Department of Metabolism and Endocrinology, Fukuoka Medical Association Hospital, Fukuoka, Japan

Publication date: 2004-05-01